Targeted immunotherapy efficacy analysis in patients with relapsed/refractory B cell acute lymphocytic leukemia

• Published in: Zhōnghuá xuèyèxué zázhì Vol. 43; no. 11; p. 946
• Main Authors: Su, Y, Bao, S, Wei, Y P, Song, L J, Xue, Y M, Wei, X D, Song, Y P, Yin, Q S
• Format: Journal Article
• Language: Chinese
• Published: China 14.11.2022
• Subjects: Antigens, CD19; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Leukemia, B-cell, acute; CAR-T cell; Blinatumomab
• ISSN: 0253-2727
• DOI: 10.3760/cma.j.issn.0253-2727.2022.11.011

Comparison of conventional chemotherapy and immunotargeted therapy efficacy in patients with relapsed/refractory (R/R) acute B cell leukemia (B-ALL) . The clinical data of 212 patients with R/R B-ALL in the Affiliaed Cancer Hospital of Zhengzhou University from January 2008 to July 2020 were analyzed retrospectively to compare the response rate and survival time difference between conventional chemotherapy and immunotargeted therapies (antiCD19 CAR-T and CD3CD19 bi-specific antibody blinatumomab) , and to explore the related factors affecting prognosis. The CR rate of patients with R/R B-ALL treated with anti-CD19 CAR-T cells was 80.4% , patients treated with blinatumomab was 62.5% , and patients treated with chemotherapy was 38.6% . There was significant difference in the CR rate among the three therapies ( <0.001) . CAR-T cells 1-year OS rate was 41.5% , which was significantly higher than that of the chemotherapy group (10.3% ) ( <0.001) . The 1-year PFS rate of CAR-T cells (30.1% ) was also significantly